doxorubicin
dox
one
renown
anticanc
drug
wide
use
treat
sever
pediatr
adult
tumor
includ
breast
cancer
leukemia
lymphoma
belong
anthracyclin
famili
whose
first
constitu
daunorubicin
isol
streptomyc
peucetiu
one
key
featur
drug
abil
inhibit
topoisomeras
ii
lead
doublestrand
dna
break
thu
hamper
cellular
replic
transcript
anthracyclin
directli
intercal
dna
eventu
lead
disrupt
physiolog
proteindna
interact
eg
histonesdna
bind
associ
product
reactiv
oxygen
speci
ro
result
dna
damag
respons
pathway
perturb
doxexpos
cell
tissu
despit
doxbas
therapi
cancer
usual
provid
benefici
effect
lead
increas
surviv
rate
drugexpos
cancer
patient
tangibl
risk
suffer
advers
cardiac
effect
cardiotox
effect
rang
subclin
ventricular
dysfunct
sever
cardiomyopathi
sometim
result
need
heart
transplant
cardiotox
occur
either
acut
sever
year
treatment
occurr
difficult
predict
repres
major
risk
factor
especi
childhood
cancer
survivor
sinc
discoveri
harm
effect
dox
heart
mani
research
focus
investig
mechan
base
phenomenon
identifi
reliabl
biomark
earli
diagnosi
doxinduc
toxic
regardless
sever
hypothes
formul
year
result
decad
investig
whole
pictur
far
understood
inde
sever
mechan
action
base
druginduc
toxic
propos
experiment
corrobor
eg
induct
oxid
stress
andor
topoisomeras
inhibit
mani
remain
unveil
increas
evid
indic
doxinduc
cardiomyopathi
caus
cumul
effect
sever
perturb
pathway
particularli
dna
damag
respons
pathway
eventu
lead
death
apoptosi
cardiac
cell
patient
either
present
risk
cardiotox
usual
treat
cardioprotect
medic
angiotensinconvert
enzym
ace
inhibitor
help
mitig
side
effect
prolong
use
anthracyclin
assess
cardiotox
onset
achiev
mean
sever
approach
echocardiograph
evalu
cardiac
function
usual
measur
left
ventricular
eject
fraction
lvef
imag
endomyocardi
biopsi
howev
techniqu
present
import
limit
includ
low
sensit
high
invas
elev
cost
late
detect
heart
dysfunct
sever
investig
conduct
doxaffect
patient
led
identif
circul
easili
detect
marker
diseas
onset
thu
address
issu
abovement
diagnost
techniqu
among
other
brain
natriuret
peptid
bnp
cardiac
troponin
ctn
demonstr
highli
reliabl
adopt
robust
circul
biomark
doxinduc
cardiotox
particular
clinic
set
increas
level
plasma
bnp
associ
presenc
congest
heart
failur
hf
interestingli
congest
hf
character
impair
cardiac
contractil
elev
wall
stress
thu
present
mani
similar
latestag
doxinduc
cardiac
impair
hand
ctn
gold
standard
marker
heart
damag
releas
circulatori
system
upon
cardiac
necrosi
phenomenon
character
instanc
myocardi
infarct
myocard
nevertheless
sinc
troponin
level
increas
blood
tissu
damag
occur
exploit
earli
diagnost
marker
dysfunct
onset
consid
limit
current
biomark
urgent
need
identifi
new
stabl
highli
sensit
noninvas
biomark
recent
sever
studi
turn
attent
involv
microrna
mirna
doxinduc
toxic
mirna
repres
attract
therapeut
target
cardiac
context
due
fact
small
approxim
nucleotid
endogen
singlestrandedrna
regul
gene
express
either
inhibit
messeng
rna
mrna
translat
promot
degrad
play
key
role
mani
biolog
process
cell
differenti
replic
regener
physiolog
patholog
condit
grow
evid
shown
mirna
involv
cardiac
function
includ
conduct
electr
signal
heart
muscl
contract
growth
antimirna
oligonucleotid
complementari
sequenc
matur
mirna
use
determin
mirna
function
studi
potenti
mirnabas
drug
target
interestingli
mirna
also
repres
noninvas
specif
circul
marker
sever
cardiovascular
diseas
circul
mirna
mani
potenti
advantag
biomark
evolutionarili
conserv
among
speci
allow
translat
preclin
model
clinic
practic
ii
appear
tissuespecif
iii
demonstr
highli
stabl
time
variou
bodi
fluid
includ
plasma
serum
urin
saliva
addit
mirna
level
assess
differ
sensit
techniqu
quantit
realtim
pcr
rtqpcr
nextgener
sequenc
mani
research
group
focus
attent
vivo
studi
order
tri
confirm
result
publish
vitro
studi
concern
dox
mirna
time
attempt
overcom
limit
obviou
reason
possibl
studi
mechan
govern
cardiotox
directli
cancer
patient
thu
clinic
relev
anthracyclineinduc
chronic
cardiotox
trigger
mani
investig
base
use
anim
model
rat
mice
shed
light
sever
effect
dox
treatment
vivo
studi
import
cardiac
field
also
exampl
establish
teratogen
potenti
compound
harm
effect
liver
howev
preval
focu
doxbas
preclin
studi
cardiotox
sever
investig
conduct
year
allow
establish
robust
reliabl
anim
model
thu
lead
import
find
term
unforeseen
interact
dox
drug
discoveri
cardioprotect
molecul
treatment
contrast
heart
failur
onset
progress
assess
new
formul
protocol
drug
deliveri
present
overview
past
recent
studi
conduct
investig
role
mirna
doxmedi
cardiac
dysfunct
discuss
strength
limit
present
work
summar
tabl
result
depict
fig
clariti
sake
decid
discuss
separ
tissuebas
studi
investig
circul
mirna
hori
colleagu
first
publish
manuscript
suggest
perturb
mirna
express
anim
model
doxinduc
cardiotox
author
describ
signific
reduct
receptor
tyrosin
kinas
express
heart
mice
day
treatment
mgg
dox
sinc
proteasom
partial
involv
druginduc
downregul
mirna
hypothes
possibl
mediat
drug
effect
particular
select
candid
abund
express
heart
potenti
target
mrna
inde
vitro
experi
neonat
rat
cardiomyocyt
nrcm
show
decreas
protein
express
concomit
increas
level
upon
treatment
dox
h
interestingli
overexpress
cell
led
decreas
protein
level
transcript
luciferas
experi
confirm
bonafid
target
result
along
observ
concomit
dox
treatment
overexpress
increas
cell
death
revert
ectop
express
led
author
hypothes
doxinduc
apoptosi
could
result
mediat
downregul
despit
massiv
extent
vitro
result
exist
mechan
induct
vivo
substanti
causal
mechan
doxinduc
cardiac
toxic
support
experiment
data
surprisingli
author
evalu
express
anim
model
thu
claim
physiolog
role
mirna
doxinduc
cardiotox
onset
regard
specul
anoth
potenti
issu
work
amount
drug
administ
mice
remark
author
indic
manuscript
drugtreat
anim
receiv
mgg
doxorubicin
amount
would
startlingli
high
comparison
medium
dose
usual
administ
kind
experi
mgkg
care
evalu
manuscript
indic
refer
anim
treatment
reveal
correct
quantiti
drug
administ
anim
mgkg
fu
colleagu
publish
work
investig
possibl
effect
doxtreat
cardiac
mirna
express
vivo
although
exact
reason
behind
choic
g
focu
investig
clear
author
use
adult
male
wistar
albino
rat
divid
four
group
intraperiton
administ
either
salin
mgkg
dox
everi
day
cumul
dose
mgkg
notabl
one
control
group
establish
treat
similarli
dox
mgkg
cohort
rat
sacrif
h
last
inject
predefin
cumul
dose
amount
reach
gener
indic
heart
function
measur
assess
cardiotox
onset
bodi
weight
heart
rate
puls
pressur
plasma
cardiac
troponin
ctnt
concentr
heart
organ
coeffici
clearli
defin
marker
realli
relat
cardiac
damag
ctnt
show
slight
signific
increas
mgkg
group
vs
control
anim
note
investig
show
valu
bodi
weight
paramet
day
mgkg
dox
group
group
describ
reach
target
cumul
dose
administr
day
respect
sacrif
h
later
strang
express
data
heart
report
perform
eight
ratsgroup
five
anim
group
indic
method
section
addit
clear
exhaust
descript
small
nuclear
rna
snrna
adopt
normal
besid
statement
appear
present
cell
vivo
present
signific
downregul
mgkg
doxtreat
mice
group
togeth
decreas
heart
rate
express
mirna
declin
also
acut
h
drug
administr
concentr
rang
primari
cardiac
cell
isol
wistar
albino
rat
cell
viabil
visual
regist
beat
frequenc
neg
affect
well
observ
discrep
term
time
dysfunct
onset
vivo
vitro
experi
could
due
system
respons
druginduc
damag
anim
obvious
lack
cultur
cell
addit
author
specul
role
mirna
doxinduc
cardiotox
claim
plasma
concentr
doxinduc
heart
injuri
model
show
good
correl
ctnt
indic
cardiac
function
unfortun
data
shown
part
manuscript
remark
author
focus
discuss
mostli
complet
data
literatur
possibl
target
conceiv
involv
heart
impair
effect
drug
attempt
experiment
verifi
specul
present
conclus
contribut
work
understand
mechan
doxinduc
cardiotox
occurr
clearli
appreci
year
vacchisuzzi
colleagu
report
chronic
myocardi
toxic
induc
dox
rat
associ
modul
sever
mirna
transcript
sever
cardiomyopathyrel
gene
studi
six
male
ratsgroup
inject
week
respect
dox
mgkg
dexrazoxan
dzr
cardioprotect
agent
mgkg
combin
dox
mgkg
dzr
etoposid
ep
topoisomeras
ii
inhibitor
devoid
cardiovascular
toxic
mgkg
salin
week
thu
cumul
dosag
dox
rang
mgkg
notabl
anim
surviv
week
dose
dox
mgkgweek
possibl
druginduc
system
damag
although
caus
death
indic
indic
cardiotox
author
report
dox
induc
macro
microvacuol
cardiac
myocyt
atria
ventricl
fraction
undergo
vacuol
small
administr
mgkgweek
dox
induc
timedepend
modul
express
cardiac
mrna
previous
associ
molecular
respons
cardiomyopathi
follow
heart
damag
onset
author
conduct
mirna
screen
rat
treat
mgkg
dox
cumul
dose
profil
rodent
mirna
use
taqman
lowdens
array
qpcr
platform
detect
approxim
microrna
sampl
arbitrarili
choos
snrna
intern
normal
compar
control
anim
mgkg
dox
group
show
appreci
perturb
mirna
express
mgkg
cumul
dose
led
increas
level
mirna
decreas
mirna
among
subset
mirna
lowest
nomin
p
valu
select
valid
use
singl
taqman
assay
perform
anim
four
group
treat
mgkg
dox
five
mirna
display
consist
respons
dox
chosen
express
profil
across
studi
group
case
anim
treat
dox
alon
author
observ
slight
upregul
heart
anim
treat
mid
mgkg
high
mgkg
dose
dox
week
week
level
five
mirna
significantli
increas
dose
depend
observ
week
level
significantli
increas
dose
depend
difficult
assess
sinc
two
anim
surviv
highdos
group
dzr
treatment
affect
physiolog
express
investig
mirna
interestingli
cardioprotect
agent
abl
contrast
doxinduc
mirna
upregul
despit
abl
suggest
shown
author
lessen
magnitud
doxinduc
vacuol
among
epsadminist
anim
minim
perturb
observ
regardless
dose
time
taken
togeth
data
suggest
doxspecif
regul
investig
microrna
interestingli
express
three
five
mirna
show
posit
correl
sever
cardiac
tissu
lesion
inde
increas
dose
dox
led
higher
vacuol
grade
parallel
progress
stronger
upregul
note
although
lowdos
treatment
caus
detect
vacuol
author
observ
signific
increas
group
result
suggest
doxinduc
perturb
specif
cardiac
mirna
preced
possibl
trigger
histopatholog
lesion
cardiotox
potenti
major
point
interest
work
reli
genomewid
gene
express
profil
conduct
along
mirna
screen
potenti
allow
author
investig
mirnatarget
interact
function
relev
cardiac
respons
drug
surprisingli
bioinformat
predict
show
find
worth
report
conclus
predict
potenti
cluster
mirna
earli
tissu
indic
druginduc
cardiac
lesion
repres
major
find
work
remark
though
real
direct
evalu
cardiac
function
conduct
besid
histolog
assess
cellular
damag
identifi
biomark
earli
doxinduc
cardiac
tissu
damag
also
scope
desai
collabor
paper
publish
investig
express
mirna
heart
male
mice
chronic
treat
inject
intraven
mgkg
dox
salin
week
week
result
respect
cumul
dox
dose
mgkg
interestingli
author
chose
sacrific
anim
week
cumul
dox
exposur
presenc
cardiac
injuri
determin
base
ctnt
plasma
level
significantli
increas
mice
expos
cumul
dox
dose
mgkg
note
mous
ctnt
plasma
concentr
measur
use
elecsi
troponin
stat
assay
roch
diagnost
design
routin
adopt
detect
ctnt
human
origin
data
valid
reliabl
rodent
model
provid
histolog
assess
cardiac
cell
damag
also
conduct
light
microscopi
remark
mgkg
dox
group
show
sign
cardiac
lesion
albeit
sever
minim
unfortun
imag
assess
cardiac
function
perform
despit
lack
evid
heart
lesion
mice
expos
dox
mgkg
author
use
agil
mous
mirna
microarray
investig
express
uniqu
mirna
total
sampl
treatment
cumul
exposur
sampl
per
group
two
heart
mice
treatment
group
compar
ctnt
plasma
concentr
pool
use
total
rna
extract
interestingli
express
show
signific
increas
dox
dose
confirm
singl
rtqpcr
assay
indic
earli
molecular
marker
cardiac
tissu
injuri
dox
treatment
note
drug
exposur
mgkg
influenc
express
mirna
besid
hypertrophyrel
mirna
increas
dose
cardiac
upregul
four
mirna
togeth
rise
plasma
ctnt
concentr
mgkg
dox
might
suggest
associ
cardiac
damag
unfortun
lack
assess
cardiac
function
allow
strong
conclus
hypothesi
tong
colleagu
investig
behavior
singl
specif
mirna
respons
doxtrigg
cardiotox
mous
model
choic
driven
known
activ
mirna
cardiovascular
diseas
includ
myocardi
infarct
cardiac
fibrosi
antiapoptot
function
ischemiareperfus
hypoxiareoxygenationinduc
cardiomyocyt
apoptosi
author
use
wildtyp
balbc
male
mice
mimic
acut
chronic
dox
administr
acut
set
adox
mice
continu
inject
intraperiton
either
salin
dox
day
cumul
dose
mgkg
chronic
set
cdox
mice
inject
dox
mgkgweek
week
cumul
dose
mgkg
anim
sacrif
day
reach
cumul
dose
follow
assess
cardiotox
cardiac
hemodynam
measur
dox
treatment
result
diminish
surviv
rate
depress
cardiac
function
decreas
heart
indic
heart
weightbodi
weight
ratio
cardiac
injuri
pronounc
cdox
group
confirm
apoptosi
evalu
tunel
assay
assess
express
level
perform
vivo
vitro
singl
rtqpcr
assay
arbitrarili
use
snrna
intern
refer
notabl
show
modest
increas
vs
control
myocardium
chronic
treat
anim
perturb
found
acut
treat
anim
moreov
rate
apoptosi
high
cdox
group
less
increas
adox
group
vs
respect
comparison
control
valu
indic
appear
around
follow
vitro
experi
use
doxtreat
h
heart
tissuederiv
cell
dosedepend
increas
express
level
detect
transfect
cell
mimic
molecul
induc
mild
increas
express
mirna
transfect
synthet
inhibitor
led
reduct
decreas
apoptosi
observ
overexpress
doxtreat
cell
increas
regist
use
inhibitor
curious
author
show
effect
modul
absenc
dox
follow
bioinformat
predict
target
experi
perform
investig
express
b
cell
transloc
gene
key
gene
involv
cell
differenti
prolifer
dna
damag
repair
apoptosi
cancer
cell
express
decreas
myocardium
doxadminist
anim
cell
treat
drug
takehom
messag
author
indic
cardiomyocyt
protector
suggest
regul
might
contrast
doxinduc
injuri
howev
despit
valid
bonafid
target
role
apoptosi
remain
unclear
addit
parallel
strong
increas
apoptot
rate
express
vivo
seem
contrast
known
antiapoptot
activ
mirna
vitro
result
one
articul
investig
term
experiment
design
publish
year
rocaalonso
cowork
case
author
chose
take
advantag
combin
result
three
differ
model
cardiotox
order
identifi
robust
heartdamag
respons
mirna
signatur
particular
two
model
cardiac
injuri
compar
male
rat
proxim
left
anterior
descend
lad
coronari
arteri
ligat
induc
myocardi
infarct
mi
dox
administr
mi
anim
sacrif
week
surgeri
heart
explant
doxtreat
model
rat
administ
cumul
dose
mgkg
dox
deliv
via
six
intraperiton
inject
week
sacrif
week
last
inject
anim
constantli
monitor
sign
hf
inde
dilat
cardiomyopathi
occurr
demonstr
reduct
left
ventricular
lv
systol
function
sacrific
addit
doxtreat
heart
show
increas
lv
endsystol
enddiastol
volum
reduc
contract
effici
use
pressurevolum
analysi
consist
dilat
cardiomyopathi
phenotyp
remark
cardiac
function
assess
shown
mi
group
sacrific
ventricl
separ
atria
use
obtain
cardiac
cell
mi
dox
rat
cardiomyocyt
isol
base
centrifug
speed
size
viabl
cell
select
plate
lamininco
plate
use
third
model
consist
rodent
ventricular
cardiomyocyt
deriv
control
rat
treat
vitro
h
dox
dose
author
state
clinic
relev
regrett
author
gave
indic
method
use
establish
clinic
relev
drug
concentr
number
treat
cell
method
use
rna
extract
perform
mirna
profil
use
ncounter
rat
mirna
express
assay
three
differ
model
evalu
result
obtain
compar
treat
vs
control
evidenc
seven
mirna
perturb
express
group
remark
show
reduc
express
comparison
control
author
select
valid
rtqpcr
vitro
snrna
arbitrarili
chosen
normal
good
correl
observ
profil
valid
result
sinc
three
member
famili
downregul
least
two
model
author
focus
attent
pathway
enrich
analysi
put
target
reveal
potenti
implic
cardiomyopathi
inde
express
seem
attenu
contractil
respons
cardiomyocyt
stimul
similarli
ratio
indic
suscept
cell
apoptosi
show
decreas
doxtreat
cardiac
cultur
cell
upon
overexpress
indic
benefici
effect
express
cardiac
cell
viabil
support
import
famili
doxrespons
author
propos
mechan
regul
inhibit
cluster
transcript
transcript
factor
known
play
key
role
cardiac
develop
inde
show
dox
treatment
could
induc
express
thu
trigger
downregul
result
led
author
conclud
famili
potenti
cardioprotect
molecul
anthracyclineinduc
cardiotox
studi
first
address
potenti
involv
famili
respons
dox
possibl
open
door
futur
therapeut
applic
unfortun
state
author
experi
address
issu
could
done
due
restrict
appli
anim
experiment
uk
thu
despit
use
anim
model
investig
consid
vitro
studi
entir
clear
author
decid
isol
cardiomyocyt
instead
investig
mirna
level
whole
heart
tissu
anoth
consider
made
choic
vivo
model
lad
ligat
induc
tissu
necrosi
lv
doxinduc
injuri
character
system
damag
tissu
includ
cardiac
district
sinc
cardiomyocyt
isol
conduct
use
ventricl
unbal
cell
origin
either
rv
lv
could
impact
final
result
interestingli
almost
concomit
work
shen
colleagu
suggest
inhibit
famili
express
protect
cardiac
ischem
injuri
mous
model
contrast
data
cast
doubt
real
role
mirna
heart
damag
later
studi
toni
cowork
investig
potenti
contrast
dox
cardiotox
known
heart
specif
role
respons
cardiac
stress
use
femal
balbc
mice
three
differ
set
shamtreat
doxtreat
doxplusantagomirtr
anim
sham
doxtreat
mice
inject
salin
tail
vein
day
administ
either
phosphat
buffer
solut
pb
singl
intraperiton
dose
dox
mgkg
respect
similarli
antagomir
mice
administ
nmol
day
treat
dox
mgkg
followup
mice
sacrif
heart
explant
regrett
scrambl
antagomir
use
control
silenc
effect
note
high
lethal
rate
observ
dox
mice
reduc
antagomirtr
anim
day
author
observ
moder
upregul
fourfold
dox
heart
tissu
comparison
sham
mice
group
show
regul
drug
remark
author
gave
indic
normal
express
level
perform
transcript
factor
involv
cardiac
develop
hypertrophi
known
target
neg
regul
dox
group
antagomir
revert
effect
interestingli
previou
studi
show
doxinduc
cardiomyocyt
apoptosi
least
part
mediat
suggest
role
pathway
possibl
exploit
mirna
avert
toxic
effect
drug
cardiomyocyt
order
prove
point
measur
antiapoptot
gene
express
level
apoptosi
rate
heart
sampl
dox
antagomirtr
mice
sham
mice
show
slight
increas
antagomir
group
consist
author
observ
augment
apoptosi
rate
dox
mice
heart
appear
counteract
blockag
besid
molecular
effect
treat
mice
specif
antagomir
seem
function
implic
prevent
cardiac
dysfunct
conclus
author
suggest
inhibit
could
benefici
applic
attenu
doxinduc
myocyt
apoptosi
use
system
administ
antimir
explor
mirna
function
rodent
primat
previous
propos
thu
articl
toni
cowork
support
potenti
compound
new
class
therapeut
diseaseassoci
mirna
recent
studi
yin
colleagu
investig
express
induc
cardiotox
vivo
limit
group
human
plasma
sampl
work
male
mice
acut
treat
dox
singl
intraperiton
inject
mgkg
salin
day
organ
collect
group
previous
report
contribut
atherogenesi
start
observ
investig
possibl
regul
dox
even
rational
clear
manuscript
describ
slight
upregul
level
arbitrarili
normal
snrna
express
heart
lung
kidney
liver
doxtreat
anim
similarli
observ
compar
regul
huvec
cell
treat
dox
h
base
result
author
focus
possibl
mechanist
role
doxinduc
cardiotox
use
recombin
adenoassoci
viru
raav
modul
express
vivo
particular
mirna
upregul
obtain
use
raav
vector
contain
express
cassett
inhibit
obtain
tough
decoy
rna
tud
technolog
total
five
treatment
group
investig
dox
alon
ctrl
dox
raav
express
gfp
gfpraav
dox
raav
dox
raav
inhibit
dox
raav
express
mutat
evalu
express
show
doxmedi
upregul
fourfold
vs
control
addit
increas
treatment
sixfold
vs
control
mirna
inhibit
led
reduct
vs
ctrl
gfpraav
echocardiographi
show
detriment
effect
overexpress
heart
function
slight
improv
observ
mice
treat
inhibitor
normal
heart
function
though
far
recov
noteworthi
effect
modul
vivo
without
concomit
dox
treatment
investig
interestingli
drug
induc
upregul
cardiac
mrna
level
bnp
secret
ventricl
respons
excess
stretch
increas
sever
cardiovascular
patholog
increas
contrast
inhibit
show
mild
abil
attenu
cardiac
impair
due
drug
sinc
endotheli
cell
injuri
key
event
vascular
injuri
author
investig
possibl
role
phenomenon
treat
huvec
dox
inde
drug
induc
impair
endotheli
cell
migrat
tube
format
moreov
inhibit
reliev
doxinduc
inhibit
cell
prolifer
promot
apoptosi
overexpress
aggrav
effect
similarli
huvec
transfect
exhibit
impair
nitric
oxid
releas
tube
format
cell
migrat
target
predict
author
valid
vegf
target
vitro
impli
vegf
pathway
could
possibl
mediat
respons
dox
nonetheless
sinc
led
neither
benefici
effect
mortal
rate
function
recoveri
clinic
applic
mirna
therapeut
agent
dox
cardiotox
seem
unlik
note
express
measur
first
time
also
blood
patient
acut
myelogen
leukemia
aml
treat
anthracyclinecombin
chemotherapi
circul
level
found
downregul
five
doxaml
subject
compar
five
control
donor
inform
given
type
sampl
analyz
plasma
whole
blood
time
sampl
collect
process
importantli
assess
cardiotox
onset
patient
addit
comparison
healthi
donor
question
treatment
impli
sever
cycl
drug
administr
case
baselin
level
mirna
express
assess
therapi
use
refer
major
caus
druginduc
cardiomyopathi
prolong
activ
myocardi
autophagi
gener
autophagi
cellregul
mechan
allow
turnov
cellular
compon
dysregul
balanc
result
tissu
damag
recent
emerg
key
player
autophagi
thu
lai
cowork
focus
attent
involv
cardiaccel
autophagi
process
addit
sinc
sever
studi
point
benefici
action
cardiac
function
reduct
angiotensin
iimedi
cardiac
hypertrophi
fibrosi
investig
possibl
role
autophagi
inde
although
direct
evid
link
process
overexpress
observ
murin
autophagydefici
embryon
fibroblast
male
spraguedawley
rat
divid
three
group
control
untreat
rat
doxtreat
rat
recombin
human
administ
doxtreat
rat
regrett
number
anim
use
treatment
indic
cardiomyopathi
induc
intraperiton
administr
six
dose
drug
week
mgkg
cumul
dose
addit
mgkg
given
week
mgkg
total
dose
dox
administr
four
week
treatment
dox
rat
develop
progress
decreas
cardiac
function
measur
echocardiographi
compar
control
mortal
rate
observ
contrari
administr
greatli
improv
cardiac
paramet
almost
undistinguish
untreat
anim
evalu
famili
express
normal
snrna
heart
tissu
rat
show
mark
decreas
mirna
doxadminist
anim
note
treatment
increas
express
result
keep
previous
publish
result
report
downregul
adult
rat
ventricular
cardiomyocyt
deriv
doxtreat
rat
interestingli
anim
treat
dox
show
reduc
autophagi
apoptosi
comparison
dox
anim
indic
level
cytosol
form
ii
ratio
caspas
activ
respect
addit
sinc
target
author
modul
express
primari
cardiomyocyt
found
overexpress
attenu
doxinduc
cell
apoptosi
inhibit
revers
heartprotect
effect
result
hint
possibl
therapeut
applic
autophagi
regul
contrast
detriment
effect
dox
treatment
possibl
via
among
known
mirna
involv
cardiac
function
famili
member
particip
cell
cycl
senesc
apoptosi
differenti
heart
respons
stress
particular
earlier
studi
show
therapeut
effect
inhibit
potenti
cardioprotect
intervent
moreov
indic
possibl
plasma
biomark
hf
onset
follow
acut
myocardi
infarct
recent
investig
piegari
colleagu
explor
dox
effect
express
rat
cardiac
progenitor
cell
rcpc
studi
predict
capac
circul
biomark
cardiac
damag
possibl
role
protect
heart
chemotherapyrel
toxic
firstli
express
arbitrarili
normal
use
snrna
evalu
upon
treatment
dox
h
rcpc
cardiac
fibroblast
cf
isol
femal
fisher
rat
heart
rat
embryon
myoblast
cell
rat
aortic
endotheli
cell
raoec
increas
found
rcpc
raoec
cultur
media
cf
cell
sinc
previou
work
indic
cpc
loss
caus
anthracyclin
toxic
author
evalu
whether
block
could
contrast
phenomenon
inde
inhibit
h
dox
administr
reduc
cytotox
effect
drug
significantli
increas
rcpc
vital
prolifer
importantli
treatment
affect
dox
cytotox
activ
breast
cancer
cell
even
antimirna
use
concentr
time
higher
concentr
rcpc
previou
work
shown
trigger
apoptosi
tumor
cell
cardiomyocyt
addit
author
investig
whether
could
affect
also
cell
death
inde
tunel
assay
show
mark
reduct
apoptot
cell
inhibit
doxrcpc
note
express
known
target
evalu
rtqpcr
western
blot
significantli
increas
antimirna
administr
mrna
protein
level
remark
inhibit
result
also
upregul
thu
protect
rcpc
doxinduc
damag
cell
senesc
fact
solid
target
regul
cell
cycl
surviv
senesc
one
major
novelti
work
attempt
measur
paracrin
effect
secret
rcpc
cell
inde
author
use
condit
media
doxtreat
rcpc
without
inhibit
cultur
cell
cf
raoec
h
observ
reduct
apoptosi
senesc
raoec
cell
cf
curious
cell
usual
adopt
differ
growth
media
rcpc
affect
condit
medium
author
indic
plausibl
paracrin
effector
without
discuss
possibl
molecul
secret
cell
upon
treatment
addit
suggest
pharmacolog
inhibit
could
revert
effect
present
experiment
evid
use
previous
establish
anim
model
doxinduc
cardiotox
author
investig
whether
drug
could
trigger
secret
heart
tissu
particular
rat
administ
cumul
dose
dox
mgkg
six
intraperiton
inject
period
week
treat
control
anim
sacrif
week
first
inject
cardiac
function
assess
echocardiographi
dox
anim
show
lv
dysfunct
decreas
lvef
fraction
shorten
evalu
express
normal
snrna
indic
doxinduc
upregul
heart
liver
kidney
skelet
muscl
baselin
level
higher
cardiac
tissu
organ
doxtrigg
increas
modest
heart
pronounc
liver
skelet
muscl
situ
hybrid
heart
section
doxtreat
rat
confirm
increas
rcpc
identifi
ckitposit
cell
parallel
tissu
express
plasma
exosom
fraction
isol
doxtreat
rat
found
highli
enrich
respect
control
anim
author
conclud
variat
express
peripher
circul
could
potenti
use
marker
doxinduc
cardiac
damag
although
provid
evid
specif
restrict
releas
heart
besid
mechanist
role
cardiac
tissu
mirna
start
investig
also
circul
marker
druginduc
dysfunct
oliveiracarvalho
colleagu
test
hypothesi
cardiacspecif
could
exploit
biomark
doxinduc
heart
dysfunct
breast
cancer
patient
first
time
evalu
express
level
plasma
femal
patient
first
round
chemotherapi
particular
evalu
conduct
week
treatment
dox
cyclophosphamid
paclitaxel
docetaxel
time
cardiac
damag
assess
measur
serum
ctni
lvef
echocardiographi
myocardi
injuri
consid
present
ctni
serum
level
refer
valu
pgml
signific
decreas
lvef
respect
baselin
valu
indic
occurr
cardiac
dysfunct
seven
subject
patient
show
sign
cardiotox
increas
ctni
reduc
lvef
vs
unaffect
subject
unfortun
indic
time
tempor
extent
abovement
variat
report
apart
troponin
peak
week
follow
assess
heart
damag
author
evalu
express
disappointingli
detect
sampl
absenc
inhibitor
technic
issu
demonstr
detect
author
comment
result
hint
circul
could
increas
acut
heart
injuri
shown
previous
publish
studi
conclud
probabl
releas
bloodstream
chronic
injur
heart
therefor
repres
use
biomark
doxinduc
cardiotox
breast
cancer
patient
start
publicli
avail
analys
mirna
express
profil
rat
tissu
nishimura
group
identifi
sever
mirna
high
express
cardiac
skelet
muscl
idea
base
studi
highli
express
tissuespecif
mirna
strong
probabl
repres
circul
indic
damag
detail
author
investig
possibl
use
group
select
mirna
plasma
biomark
cardiotox
anim
model
male
rat
ie
heartspecif
heart
skelet
musclespecif
skelet
musclespecif
snrna
use
arbitrarili
chosen
intern
control
end
administ
ratsgroup
singl
intraven
dose
either
dox
mgkg
isoproterenol
mgkg
known
cardiacdamag
agent
equival
volum
salin
blood
sampl
collect
h
treatment
heartspecif
significantli
increas
plasma
isoproterenoltr
rat
doxtreat
rat
earli
h
administr
three
heartmuscl
mirna
show
upregul
isoproterenol
dox
treatment
although
former
trigger
mark
respons
term
durat
extent
regul
interestingli
skelet
musclespecif
increas
dox
isoproterenoltr
anim
data
along
observ
plasma
cardiac
troponin
ctni
ctnt
increas
isoproterenoltr
rat
dox
rat
opposit
result
skelet
tnt
plasma
level
clearli
indic
isoproterenol
trigger
detect
cardiac
toxic
inde
subsequ
experi
anim
treat
day
repeat
dose
isoproterenol
show
histolog
evid
cardiac
damag
author
conclud
consid
promis
plasma
biomark
cardiotox
rat
previous
propos
other
first
work
cast
doubt
abil
dox
caus
cardiotox
although
could
possibl
due
erron
choic
evalu
cardiac
damag
maker
inde
lack
histopatholog
find
acut
dox
treatment
surpris
would
expect
chronic
set
follow
studi
rigaud
cowork
took
advantag
branch
cecci
trial
clinicaltrialsgov
investig
suitabl
select
cluster
mirna
possibl
circul
marker
cardiotox
particular
enrol
femal
patient
undergo
chemotherapi
cycl
dox
cumul
dose
cyclophosphamid
everi
week
follow
paclitaxel
week
docetaxel
everi
week
three
week
cycl
evalu
express
plasma
togeth
ctni
choic
mirna
base
previou
literatur
regard
earli
circul
biomark
myocardi
injuri
hf
andor
druginduc
cardiotox
curious
cite
literatur
refer
heart
tissu
modul
circul
level
doxtreat
anim
must
note
almost
mirna
inde
previous
propos
circul
marker
cardiac
diseas
thu
choic
strongli
support
literatur
convers
select
probabl
dictat
suppos
regul
dox
vivo
treatment
cardiac
function
assess
echocardiographi
baselin
cycl
dox
administr
month
begin
chemotherapi
cardiotox
defin
reduct
lvef
respect
baselin
andor
valu
lvef
chemotherapi
mean
plasma
level
ctni
increas
cycl
baselin
end
dox
treatment
although
chang
statist
signific
probabl
great
variabl
observ
similarli
lvef
show
modest
although
statist
signific
decreas
trend
baselin
cycl
patient
cardiotox
differ
lvef
valu
cardiotoxicityaffect
vs
unaffect
subject
widen
even
followup
high
variabl
observ
patient
show
heart
dysfunct
hamper
reach
statist
signific
analyz
mirna
express
author
confirm
use
circul
marker
due
undetect
convers
detect
show
appreci
variat
express
associ
cardiotox
onset
contrari
show
increas
trend
time
subject
comparison
baselin
level
signific
upregul
cardiotoxicityaffect
vs
noncardiotox
patient
cycl
moreov
circul
mirna
whose
express
level
associ
chang
lvef
show
also
better
area
curv
score
ctni
vs
discrimin
patient
affect
cardiotox
unaffect
subject
interest
find
work
detect
mirna
show
increas
trend
treatment
patient
albeit
without
statist
signific
possibl
explan
might
resid
normal
strategi
mirna
express
level
done
use
exogen
ad
control
mirna
inde
method
take
account
possibl
variat
total
rna
amount
sampl
fix
volum
plasma
use
dox
treatment
acut
phase
may
increas
oxid
stress
inflamm
turn
could
result
increas
circul
rna
level
although
mere
specul
driven
person
observ
choic
endogen
mirna
refer
could
address
issu
addit
admit
author
choic
investig
limit
number
mirna
greatli
hinder
chanc
identifi
robust
specif
marker
toxic
moreov
complex
dose
schedul
chemotherapi
administr
use
multipl
drug
limit
followup
sampl
size
strongli
affect
result
work
anyway
consid
start
point
studi
subject
recent
leger
cowork
publish
first
investig
regard
plasma
mirna
potenti
biomark
cardiotox
children
young
adult
treat
anthracyclin
chemotherapi
work
author
use
taqman
array
card
screen
candid
mirna
base
propos
role
circul
biomark
cardiovascular
diseas
anthracyclinebas
noncardiotoxicagentsbas
chemotherapi
cancer
patient
subject
classifi
belong
differ
group
base
troponin
elev
ac
patient
seven
acut
troponin
elev
postac
ctnt
concentr
ngl
compar
baselin
eight
chronic
troponin
elev
postac
ctnt
concentr
ngl
compar
baselin
nine
ac
patient
show
ctnt
increas
time
point
three
mirna
identifi
present
signific
upregul
anthracyclin
ac
patient
regardless
ctnt
increas
vs
control
earli
h
therapi
administr
use
normal
remain
increas
h
interestingli
express
seem
also
correl
extent
anthracyclineinduc
injuri
measur
dose
high
sensit
ctnt
work
evidenc
potenti
plasma
mirna
earli
marker
anthracyclinemedi
injuri
relev
categori
tumor
patient
children
young
adult
sinc
cardiotox
preval
longterm
cancer
survivor
known
high
remark
author
heterogen
low
sampl
size
investig
group
limit
clinic
relev
work
time
repres
first
step
toward
new
gener
biomark
earli
identif
patient
high
risk
anthracyclineinduc
cardiomyopathi
last
year
sever
group
took
advantag
differ
anim
model
doxinduc
cardiotox
order
tri
unravel
role
mirna
harm
side
effect
drug
differ
vitro
studi
anim
model
present
clear
advantag
close
mimicri
clinic
set
unfortun
number
issu
greatli
limit
knowledg
gain
studi
common
featur
among
review
public
decis
elect
investig
mostli
cardiac
enrich
mirna
eg
choic
obvious
led
strong
limit
novelti
potenti
new
find
moreov
key
issu
lessthanoptim
assess
cardiotox
inde
often
onset
heart
dysfunct
directli
verifi
either
instrument
evalu
eg
echographi
dosag
circul
marker
eg
troponin
thu
correl
mirna
express
cardiotox
assum
without
verif
anoth
limit
lack
clear
detail
descript
method
use
mani
studi
inde
author
gener
refer
heart
sampl
without
specifi
whether
whole
heart
part
use
analysi
thu
make
comparison
differ
investig
difficult
gener
clear
need
increas
consist
method
use
final
issu
paramount
import
regard
normal
strategi
robust
assess
mirna
express
rtqpcr
strongli
affect
reproduc
result
taken
serious
consider
possibl
exploit
circul
mirna
biomark
dox
cardiotox
onset
inde
humanbas
studi
pose
greater
challeng
anim
model
high
variabl
medic
protocol
patient
respons
difficulti
patient
recruit
long
medic
followup
thu
accur
wide
accept
research
protocol
implement
adopt
achiev
reproduc
among
differ
research
group
pave
way
result
strong
clinic
relev
